Palatin Technologies (PTN) Cash from Operations (2010 - 2026)
Palatin Technologies' (PTN) quarterly Cash from Operations came in at 4417063.0 in Q1 2026, up 17.5% YoY from 3759074.27 in Q1 2025, and up 8.11% on a QoQ basis from 4806845.0 in Q4 2025.
Palatin Technologies (PTN) Cash from Operations (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Cash from Operations data on file, last reported at 4417063.0 in Q1 2026.
- Quarterly Cash from Operations rose 17.5% year-over-year to 4417063.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14932332.0 (up 36.97% YoY) and the FY2025 annual result came in at 21306637.0, up 32.28% from the prior year.
- Cash from Operations improved to 4417063.0 in Q1 2026, from 4806845.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1408317.0 in Q1 2023 to a low of 10475686.0 in Q4 2023.
- A 5-year average of 6476061.76 and a median of 6472456.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 4140.77% — and 2023, when it jumped 85.16%.
- Tracing PTN's Cash from Operations over 5 years: stood at 9675945.0 in 2022, then slipped by 8.27% to 10475686.0 in 2023, then soared by 53.73% to 4847106.0 in 2024, then rose by 0.83% to 4806845.0 in 2025, then increased by 8.11% to 4417063.0 in 2026.
- The last three Cash from Operations figures came in at 4417063.0 (Q1 2026), 4806845.0 (Q4 2025), and 1619382.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | -4.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.42 Mn |
| Mar 31, 2026 | -4.42 Mn |
| Dec 31, 2025 | -4.81 Mn |
| Dec 31, 2025 | -4.81 Mn |
| Sep 30, 2025 | -1.62 Mn |
| Sep 30, 2025 | -1.62 Mn |
| Jun 30, 2025 | -4.09 Mn |
| Jun 30, 2025 | -4.09 Mn |
| Mar 31, 2025 | -5.35 Mn |
| Mar 31, 2025 | -5.35 Mn |
| Dec 31, 2024 | -4.85 Mn |
| Dec 31, 2024 | -4.85 Mn |
| Sep 30, 2024 | -7.02 Mn |
| Sep 30, 2024 | -7.02 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Mar 31, 2024 | -8.61 Mn |
| Mar 31, 2024 | -8.61 Mn |
| Dec 31, 2023 | -10.48 Mn |
| Dec 31, 2023 | -10.48 Mn |